首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   865325篇
  免费   71827篇
  国内免费   1844篇
耳鼻咽喉   12860篇
儿科学   24851篇
妇产科学   25173篇
基础医学   124755篇
口腔科学   25649篇
临床医学   75744篇
内科学   165513篇
皮肤病学   17045篇
神经病学   70431篇
特种医学   35521篇
外国民族医学   171篇
外科学   136586篇
综合类   24665篇
现状与发展   2篇
一般理论   273篇
预防医学   67179篇
眼科学   20583篇
药学   64907篇
中国医学   1594篇
肿瘤学   45494篇
  2018年   7384篇
  2015年   7768篇
  2014年   11200篇
  2013年   16915篇
  2012年   22876篇
  2011年   24024篇
  2010年   13963篇
  2009年   13149篇
  2008年   22722篇
  2007年   24816篇
  2006年   24699篇
  2005年   24304篇
  2004年   23889篇
  2003年   23016篇
  2002年   22092篇
  2001年   35947篇
  2000年   36628篇
  1999年   31009篇
  1998年   9272篇
  1997年   8584篇
  1996年   8519篇
  1995年   8072篇
  1994年   7766篇
  1992年   26788篇
  1991年   26214篇
  1990年   25737篇
  1989年   24803篇
  1988年   23332篇
  1987年   22982篇
  1986年   21840篇
  1985年   21203篇
  1984年   16468篇
  1983年   14066篇
  1982年   8898篇
  1981年   8233篇
  1980年   7705篇
  1979年   16804篇
  1978年   12162篇
  1977年   10206篇
  1976年   9364篇
  1975年   10177篇
  1974年   12676篇
  1973年   12190篇
  1972年   11583篇
  1971年   10720篇
  1970年   10252篇
  1969年   9924篇
  1968年   8924篇
  1967年   8252篇
  1966年   7673篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances.  相似文献   
12.
13.
14.
Objective: Human epidermal growth factor receptor 2 (erbb2/HER2) overexpression, has now been implicatedin advanced gastric and gastroesophageal junction cancers. The study was conducted to determine the rate of HER2positivity in patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma in North-EastIndia and to assess the impact of various demographic and clinical parameters on HER2 positivity. Methods: A total of68 patients of age >18 years of gastric and gastroesophageal adenocarcinoma diagnosed on histopathological examinationfrom September 2016 to February 2018 at Dr B Borooah Cancer Institute, Assam were enrolled for the observational(epidemiological) study. All patients were subjected to the HER2 immunohistochemistry test using a FDA-approved,standardized test kit. HER2 expression was correlated with various demographic and clinicopathological parameters.Results: The overall rate of HER2 positivity in the population studied was 56% (n=38). The rate was non-significantlyhigher in male, older age group (>60 years) and Hindu population. Similarly, HER2 positivity rate was higher in patientswith well differentiated histology and was more common in patients with stage II and III diseases, but neither of theassociations is statistically significant. HER2 positivity rate was significantly higher in proximal and in GEJ tumours(56% versus 44%, P=0.002). Conclusion: HER2 overexpression was evident in 56% of the North-East Indian patientswith locally advanced and metastatic gastric and gastroesophageal adenocarcinoma. The overexpression correlatedsignificantly with primary tumour site. Routine testing of gastric and gastroesophageal tumours for HER2 expressionis recommended to provide a therapeutic advantage in Indian patients.  相似文献   
15.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
16.
17.
18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号